About PolyPid
PolyPid is a company based in Petah Tikva (Israel) founded in 2008.. PolyPid has raised $96.71 million across 10 funding rounds from investors including Xenia Venture Capital, Shavit Capital and Aurum Ventures. The company has 61 employees as of December 31, 2024. PolyPid offers products and services including PLEX Platform, D-PLEX 100, and D-PLEX 1000. PolyPid operates in a competitive market with competitors including PanTher Therapeutics, Zyl Therapeutics, Santen Pharmaceuticals, Lexaria Bioscience and LabInCube, among others.
- Headquarter Petah Tikva, Israel
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Polypid Ltd.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-29.02 M-21.61as on Dec 31, 2024
-
EBITDA
$-26.41 M-25.48as on Dec 31, 2024
-
Total Equity Funding
$96.71 M (USD)
in 10 rounds
-
Latest Funding Round
$26.69 M (USD), Post-IPO
Jun 16, 2025
-
Investors
Xenia Venture Capital
& 3 more
-
Employee Count
61
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PolyPid
PolyPid is a publicly listed company on the NASDAQ with ticker symbol PYPD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PolyPid
PolyPid offers a comprehensive portfolio of products and services, including PLEX Platform, D-PLEX 100, and D-PLEX 1000. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables localized, controlled release of medications for surgical use.
Prevents surgical site infections via extended antibiotic delivery.
Targets bone-related infections with prolonged drug release.
Unlock access to complete
Unlock access to complete
Funding Insights of PolyPid
PolyPid has successfully raised a total of $96.71M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $26.69 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $26.7M
-
First Round
First Round
(23 Jan 2012)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Post-IPO - PolyPid | Valuation |
investors |
|
| Dec, 2024 | Amount | Post-IPO - PolyPid | Valuation |
investors |
|
| Aug, 2024 | Amount | Post-IPO - PolyPid | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PolyPid
PolyPid has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Xenia Venture Capital, Shavit Capital and Aurum Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in Israel are managed by Shavit Capital.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Early-stage centric life sciences and tech focused VC firm investing primarily in Israel and the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PolyPid
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PolyPid
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Polypid Comparisons
Competitors of PolyPid
PolyPid operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PanTher Therapeutics, Zyl Therapeutics, Santen Pharmaceuticals, Lexaria Bioscience and LabInCube, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Hydrogel-derived nanoparticles for topical drug delivery are developed.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Patented drug delivery technology is developed for bioactive molecules.
|
|
| domain | founded_year | HQ Location |
Drug-releasing medical devices and medicines are developed with InCube technology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Polypid
Frequently Asked Questions about PolyPid
When was PolyPid founded?
PolyPid was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Where is PolyPid located?
PolyPid is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Is PolyPid a funded company?
PolyPid is a funded company, having raised a total of $96.71M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $14.2M, raised on Jan 23, 2012.
How many employees does PolyPid have?
As of Dec 31, 2024, the latest employee count at PolyPid is 61.
What does PolyPid do?
PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oralmaxillofacial defects while protecting from infections).
Who are the top competitors of PolyPid?
PolyPid's top competitors include PanTher Therapeutics, Lexaria Bioscience and Santen Pharmaceuticals.
What products or services does PolyPid offer?
PolyPid offers PLEX Platform, D-PLEX 100, and D-PLEX 1000.
Is PolyPid publicly traded?
Yes, PolyPid is publicly traded on NASDAQ under the ticker symbol PYPD.
Who are PolyPid's investors?
PolyPid has 4 investors. Key investors include Xenia Venture Capital, Shavit Capital, Aurum Ventures, and Yellin Lapidot.
What is PolyPid's ticker symbol?
The ticker symbol of PolyPid is PYPD on NASDAQ.